"This study found that visual reads of amyloid PET studies may be insensitive when amyloidosis is milder. The quantification of amyloid PET using the CL scale may be helpful in guiding treatment of patients with mild amyloidosis who are under consideration for antiamyloid therapeutics."
November 4, 2025 at 4:41 PM
"This study found that visual reads of amyloid PET studies may be insensitive when amyloidosis is milder. The quantification of amyloid PET using the CL scale may be helpful in guiding treatment of patients with mild amyloidosis who are under consideration for antiamyloid therapeutics."
Thinking maybe Antiamyloid treatment for Alzheimer's disease. IV treatment once a month; frequent MRI’s … 🤷♀️
www.mayoclinic.org/diseases-con...
www.mayoclinic.org/diseases-con...
How Alzheimer's medicines help manage symptoms
Although there's no cure for Alzheimer's disease, certain drugs might help you manage your symptoms and improve your life for a time.
www.mayoclinic.org
October 30, 2025 at 8:50 AM
Thinking maybe Antiamyloid treatment for Alzheimer's disease. IV treatment once a month; frequent MRI’s … 🤷♀️
www.mayoclinic.org/diseases-con...
www.mayoclinic.org/diseases-con...
Antiamyloid therapies for #Alzheimer disease showed promise in removing plaque from the brain.
In the first few years after their approval, have they demonstrated clinical benefits?
In the first few years after their approval, have they demonstrated clinical benefits?
Real-World Experience With Antiamyloid Therapies for Alzheimer Disease
This Medical News article discusses the safety and effectiveness of lecanemab and donanemab in treating mild cognitive impairment and early Alzheimer disease outside clinical trials.
jamanetwork.com
September 26, 2025 at 4:10 PM
Antiamyloid therapies for #Alzheimer disease showed promise in removing plaque from the brain.
In the first few years after their approval, have they demonstrated clinical benefits?
In the first few years after their approval, have they demonstrated clinical benefits?
Ever since @fda.gov granted traditional approval to lecanemab and its competitor donanemab, clinicians have been collecting and reporting information about their real-world experience with the 2 antiamyloid monoclonal antibodies.
Learn More @jama.com Medical News
jamanetwork.com/journals/jam...
Learn More @jama.com Medical News
jamanetwork.com/journals/jam...
Real-World Experience With Antiamyloid Therapies for Alzheimer Disease
This Medical News article discusses the safety and effectiveness of lecanemab and donanemab in treating mild cognitive impairment and early Alzheimer disease outside clinical trials.
jamanetwork.com
September 2, 2025 at 1:10 PM
Ever since @fda.gov granted traditional approval to lecanemab and its competitor donanemab, clinicians have been collecting and reporting information about their real-world experience with the 2 antiamyloid monoclonal antibodies.
Learn More @jama.com Medical News
jamanetwork.com/journals/jam...
Learn More @jama.com Medical News
jamanetwork.com/journals/jam...
🎙️ Listen to the latest science published in JAMA Medical News:
➡️ What Is 7-OH?
➡️ Antiamyloid Therapies for #Alzheimer Disease
➡️ FDA Panel on #SSRIs and Pregnancy; and more.
Listen now: ja.ma/3JFrP07
➡️ What Is 7-OH?
➡️ Antiamyloid Therapies for #Alzheimer Disease
➡️ FDA Panel on #SSRIs and Pregnancy; and more.
Listen now: ja.ma/3JFrP07
August 2025 Medical News Summary
What Is 7-OH?; Real-World Experience With Antiamyloid Therapies for Alzheimer Disease; FDA Panel on SSRIs and Pregnancy Lacked Nuance, Experts Say
ja.ma
August 30, 2025 at 12:00 PM
🎙️ Listen to the latest science published in JAMA Medical News:
➡️ What Is 7-OH?
➡️ Antiamyloid Therapies for #Alzheimer Disease
➡️ FDA Panel on #SSRIs and Pregnancy; and more.
Listen now: ja.ma/3JFrP07
➡️ What Is 7-OH?
➡️ Antiamyloid Therapies for #Alzheimer Disease
➡️ FDA Panel on #SSRIs and Pregnancy; and more.
Listen now: ja.ma/3JFrP07
Real-World Experience With Antiamyloid Therapies for Alzheimer Disease jamanetwork.com/journals/jam...
Real-World Experience With Antiamyloid Therapies for Alzheimer Disease
This Medical News article discusses the safety and effectiveness of lecanemab and donanemab in treating mild cognitive impairment and early Alzheimer disease outside clinical trials.
jamanetwork.com
August 24, 2025 at 1:39 AM
Real-World Experience With Antiamyloid Therapies for Alzheimer Disease jamanetwork.com/journals/jam...
Antiamyloid therapies showing a mixed bag for Alzheimer's.
Amyloid plaques are junk proteins that build up in brains of Alz patients. Once assumed a cause, now increasingly seen as a symptom.
#science #medicine #alzheimers
Amyloid plaques are junk proteins that build up in brains of Alz patients. Once assumed a cause, now increasingly seen as a symptom.
#science #medicine #alzheimers
Real-World Experience With Antiamyloid Therapies for Alzheimer Disease jamanetwork.com/journals/jam... by @jama.com
#Alzheimers #dementia #Neuroskyence
#Alzheimers #dementia #Neuroskyence
Real-World Experience With Antiamyloid Therapies for Alzheimer Disease
This Medical News article discusses the safety and effectiveness of lecanemab and donanemab in treating mild cognitive impairment and early Alzheimer disease outside clinical trials.
jamanetwork.com
August 23, 2025 at 11:45 AM
Antiamyloid therapies showing a mixed bag for Alzheimer's.
Amyloid plaques are junk proteins that build up in brains of Alz patients. Once assumed a cause, now increasingly seen as a symptom.
#science #medicine #alzheimers
Amyloid plaques are junk proteins that build up in brains of Alz patients. Once assumed a cause, now increasingly seen as a symptom.
#science #medicine #alzheimers
Real-World Experience With Antiamyloid Therapies for Alzheimer Disease jamanetwork.com/journals/jam... by @jama.com
#Alzheimers #dementia #Neuroskyence
#Alzheimers #dementia #Neuroskyence
Real-World Experience With Antiamyloid Therapies for Alzheimer Disease
This Medical News article discusses the safety and effectiveness of lecanemab and donanemab in treating mild cognitive impairment and early Alzheimer disease outside clinical trials.
jamanetwork.com
August 22, 2025 at 9:46 PM
Real-World Experience With Antiamyloid Therapies for Alzheimer Disease jamanetwork.com/journals/jam... by @jama.com
#Alzheimers #dementia #Neuroskyence
#Alzheimers #dementia #Neuroskyence
Lecanemab vs Donanemab: antiamyloid mAb therapy for #Alzheimers:
🧠 L: lower risk of amyloid-related imaging abnormalities (ARIA)
🧠 D: infused 1x/month, L: 1x/2wks
🧠 Both: out-of-pocket ~$30k/yr
🧠 “No head-to-head study... need more randomized data"
#AlzSky #NeuroSky
#dementia #amyloid #APOE
🧠 L: lower risk of amyloid-related imaging abnormalities (ARIA)
🧠 D: infused 1x/month, L: 1x/2wks
🧠 Both: out-of-pocket ~$30k/yr
🧠 “No head-to-head study... need more randomized data"
#AlzSky #NeuroSky
#dementia #amyloid #APOE
Antiamyloid therapies for #Alzheimer disease showed promise in removing plaque from the brain. In the first few years after their approval, have they demonstrated clinical benefits?
#MedSky @ritarubin.bsky.social
#MedSky @ritarubin.bsky.social
Real-World Experience With Antiamyloid Therapies for Alzheimer Disease
This Medical News article discusses the safety and effectiveness of lecanemab and donanemab in treating mild cognitive impairment and early Alzheimer disease outside clinical trials.
jamanetwork.com
August 22, 2025 at 6:49 PM
Antiamyloid therapies for #Alzheimer disease showed promise in removing plaque from the brain. In the first few years after their approval, have they demonstrated clinical benefits?
#MedSky @ritarubin.bsky.social
#MedSky @ritarubin.bsky.social
Real-World Experience With Antiamyloid Therapies for Alzheimer Disease
This Medical News article discusses the safety and effectiveness of lecanemab and donanemab in treating mild cognitive impairment and early Alzheimer disease outside clinical trials.
jamanetwork.com
August 22, 2025 at 5:33 PM
Antiamyloid therapies for #Alzheimer disease showed promise in removing plaque from the brain. In the first few years after their approval, have they demonstrated clinical benefits?
#MedSky @ritarubin.bsky.social
#MedSky @ritarubin.bsky.social
I say something nice about the drugs in JAMA!
Real-World Experience With Antiamyloid Therapies for Alzheimer Disease url:https://jamanetwork.com/journals/jama/fullarticle/2838092?utm_source=bluesky&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=082225
Real-World Experience With Antiamyloid Therapies for Alzheimer Disease url:https://jamanetwork.com/journals/jama/fullarticle/2838092?utm_source=bluesky&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=082225
August 22, 2025 at 5:01 PM
I say something nice about the drugs in JAMA!
Real-World Experience With Antiamyloid Therapies for Alzheimer Disease url:https://jamanetwork.com/journals/jama/fullarticle/2838092?utm_source=bluesky&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=082225
Real-World Experience With Antiamyloid Therapies for Alzheimer Disease url:https://jamanetwork.com/journals/jama/fullarticle/2838092?utm_source=bluesky&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=082225
📣Have you heard of antiamyloid therapies for Alzheimer’s disease? They cause ADEs called ARIAs that are non-specific, typically require MRI, & can mimic stroke
⛔ Concomitant thrombolytics/anticoagulants are contraindicated
Learn more in our JAMA IM Clinical Insight 👇
⛔ Concomitant thrombolytics/anticoagulants are contraindicated
Learn more in our JAMA IM Clinical Insight 👇
Antiamyloid therapies for #Alzheimer disease slow cognitive decline but pose serious adverse effects like amyloid-related imaging abnormalities.
ja.ma/3V32mjt
ja.ma/3V32mjt
August 18, 2025 at 8:34 PM
📣Have you heard of antiamyloid therapies for Alzheimer’s disease? They cause ADEs called ARIAs that are non-specific, typically require MRI, & can mimic stroke
⛔ Concomitant thrombolytics/anticoagulants are contraindicated
Learn more in our JAMA IM Clinical Insight 👇
⛔ Concomitant thrombolytics/anticoagulants are contraindicated
Learn more in our JAMA IM Clinical Insight 👇
Antiamyloid therapies for #Alzheimer disease slow cognitive decline but pose serious adverse effects like amyloid-related imaging abnormalities.
ja.ma/3V32mjt
ja.ma/3V32mjt
August 17, 2025 at 1:00 PM
Antiamyloid therapies for #Alzheimer disease slow cognitive decline but pose serious adverse effects like amyloid-related imaging abnormalities.
ja.ma/3V32mjt
ja.ma/3V32mjt
Providers managing Alzheimer’s disease and the health care systems in which they work are shifting the emphasis of care from support to disease modification. Pt 2 of this series discusses care coordination challenges to safe and equitable delivery of antiamyloid monoclonal antibodies. bit.ly/3U0BUGQ
July 30, 2025 at 7:13 PM
Providers managing Alzheimer’s disease and the health care systems in which they work are shifting the emphasis of care from support to disease modification. Pt 2 of this series discusses care coordination challenges to safe and equitable delivery of antiamyloid monoclonal antibodies. bit.ly/3U0BUGQ
"Antiamyloid Therapy and Cerebral Blood Flow Changes on MRI: A Potential Longitudinal Biomarker of Treatment Response?"
doi.org/10.3174/ajnr...
@GloriaChiangMD @WCMRadiology #EditorsChoice
doi.org/10.3174/ajnr...
@GloriaChiangMD @WCMRadiology #EditorsChoice
July 16, 2025 at 3:55 PM
"Antiamyloid Therapy and Cerebral Blood Flow Changes on MRI: A Potential Longitudinal Biomarker of Treatment Response?"
doi.org/10.3174/ajnr...
@GloriaChiangMD @WCMRadiology #EditorsChoice
doi.org/10.3174/ajnr...
@GloriaChiangMD @WCMRadiology #EditorsChoice
📣Have you heard of antiamyloid therapies for AD? They cause ADEs called ARIAs that are non-specific, typically require MRI & can mimic stroke
⛔ Concomitant thrombolytics/anticoagulants are contraindicated
Learn more in our JAMA IM Clinical Insight 👉 jamanetwork.com/journals/jam...
⛔ Concomitant thrombolytics/anticoagulants are contraindicated
Learn more in our JAMA IM Clinical Insight 👉 jamanetwork.com/journals/jam...
Recognizing and Managing Adverse Effects of Antiamyloid Therapies
This clinical insight discusses the diagnosis and management of adverse effects of antiamyloid therapies and what medications require consideration or avoidance.
jamanetwork.com
June 23, 2025 at 5:39 PM
📣Have you heard of antiamyloid therapies for AD? They cause ADEs called ARIAs that are non-specific, typically require MRI & can mimic stroke
⛔ Concomitant thrombolytics/anticoagulants are contraindicated
Learn more in our JAMA IM Clinical Insight 👉 jamanetwork.com/journals/jam...
⛔ Concomitant thrombolytics/anticoagulants are contraindicated
Learn more in our JAMA IM Clinical Insight 👉 jamanetwork.com/journals/jam...
Can you give us an efficient antiamyloid therapy?
June 14, 2025 at 4:57 PM
Can you give us an efficient antiamyloid therapy?
The availability of antiamyloid therapies has heightened the need for relatively inexpensive, minimally invasive blood biomarker tests to help identify which patients with cognitive impairment have amyloid plaques in their brain, a hallmark of #Alzheimer disease. My latest for @jama.com:
The US FDA's clearance of a blood biomarker test for detecting amyloid plaques in the brain represents an advancement in #Alzheimer diagnosis and treatment, but it also raises concerns about potential misuse and overdiagnosis.
ja.ma/4kEqsMD #MedSky
ja.ma/4kEqsMD #MedSky
First Blood Test for Alzheimer Biomarkers Receives FDA Clearance
This Medical News article discusses how the first FDA-cleared blood test for Alzheimer biomarkers should and shouldn’t be used.
ja.ma
June 14, 2025 at 2:29 PM
The availability of antiamyloid therapies has heightened the need for relatively inexpensive, minimally invasive blood biomarker tests to help identify which patients with cognitive impairment have amyloid plaques in their brain, a hallmark of #Alzheimer disease. My latest for @jama.com:
New in JMIR: Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer #Disease: Systematic Review and Network Meta-Analysis With a #Web Application
Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer #Disease: Systematic Review and Network Meta-Analysis With a #Web Application
Background: Despite the increasing approval of antiamyloid antibodies for Alzheimer #Disease (AD), their clinical relevance and risk-benefit profile remain uncertain. The heterogeneity of AD and the limited availability of long-term clinical data make it difficult to establish a clear rationale for selecting one treatment over another. Objective: The aim of this work was to assess and compare the efficacy and safety of antiamyloid antibodies through an interactive #Online meta-analytic approach by performing conventional pair-wise meta-analyses and frequentist and Bayesian network meta-analyses of phase II and III #ClinicalTrial results. To achieve this, we developed AlzMeta.#app 2.0, a freely accessible #Web application that enables #Researchers and clinicians to evaluate the relative and absolute risks and benefits of these therapies in real time, incorporating different prior choices and assumptions of baseline risks of #Disease progression and adverse events. Methods: We adhered to PRISMA-NMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for reporting of systematic reviews with network meta-analysis) and GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) guidelines for reporting and rating the certainty of evidence. #ClinicalTrial reports (until September 30, 2024) were retrieved from PubMed, Google Scholar, and #ClinicalTrial databases (including ClinicalTrials.gov). Studies with
dlvr.it
April 7, 2025 at 9:03 PM
Lecanemab (Leqembi) & donanemab (Kisunla) are antiamyloid medicines approved for people with mild dementia due to Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease. Lecanemab is given as an IV infusion every two weeks. Donanemab is given as an IV infusion every four weeks.
February 28, 2025 at 8:53 PM
Lecanemab (Leqembi) & donanemab (Kisunla) are antiamyloid medicines approved for people with mild dementia due to Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease. Lecanemab is given as an IV infusion every two weeks. Donanemab is given as an IV infusion every four weeks.
ecanemab (Leqembi) & donanemab (Kisunla) are antiamyloid medicines approved for people with mild dementia due to Alzheimer's disease & mild cognitive impairment due to AD. Lecanemab is given as an IV infusion every 2 weeks. Donanemab is given as an IV infusion every 4 weeks.
Scrolling Getty and couldn't help but notice this photo of a huge bruise on Trump's hand today
February 25, 2025 at 3:20 AM
ecanemab (Leqembi) & donanemab (Kisunla) are antiamyloid medicines approved for people with mild dementia due to Alzheimer's disease & mild cognitive impairment due to AD. Lecanemab is given as an IV infusion every 2 weeks. Donanemab is given as an IV infusion every 4 weeks.
Lecanemab (Leqembi) & donanemab (Kisunla) are antiamyloid medicines approved for people with mild dementia due to Alzheimer's disease & mild cognitive impairment due to AD. Lecanemab is given as an IV infusion every 2 weeks. Donanemab is given as an IV infusion every 4 weeks.
Neither cures.
Neither cures.
February 25, 2025 at 2:35 AM
Lecanemab (Leqembi) & donanemab (Kisunla) are antiamyloid medicines approved for people with mild dementia due to Alzheimer's disease & mild cognitive impairment due to AD. Lecanemab is given as an IV infusion every 2 weeks. Donanemab is given as an IV infusion every 4 weeks.
Neither cures.
Neither cures.
In recent #Alzheimers #antiamyloid drug trials, drugmakers were accused of knowing which volunteers had a higher risk of ARIA (brain bleeds).
Here's why the companies didn't disclose that risk—and whether they did the right thing.
By @spichaksimon.bsky.social
www.beingpatient.com/alzheimers-t...
Here's why the companies didn't disclose that risk—and whether they did the right thing.
By @spichaksimon.bsky.social
www.beingpatient.com/alzheimers-t...
Some Trial Volunteers Had Higher Risk of Brain Bleeds. Here's Why Drugmakers Didn't Tell Them
Drugmakers knew which clinical trial volunteers had a higher risk of brain bleeds. Here's why they didn't warn them.
www.beingpatient.com
January 26, 2025 at 6:51 AM
In recent #Alzheimers #antiamyloid drug trials, drugmakers were accused of knowing which volunteers had a higher risk of ARIA (brain bleeds).
Here's why the companies didn't disclose that risk—and whether they did the right thing.
By @spichaksimon.bsky.social
www.beingpatient.com/alzheimers-t...
Here's why the companies didn't disclose that risk—and whether they did the right thing.
By @spichaksimon.bsky.social
www.beingpatient.com/alzheimers-t...
At #Translation2025 Prof Cath Mummery is a Keynote speaker on Trials Delivery: a critical area for assessing #dementia research discoveries and treatments. Book now.
See her most recent paper Eligibility for antiamyloid treatment zurl.co/KqOak
See her most recent paper Eligibility for antiamyloid treatment zurl.co/KqOak
December 19, 2024 at 1:47 PM
At #Translation2025 Prof Cath Mummery is a Keynote speaker on Trials Delivery: a critical area for assessing #dementia research discoveries and treatments. Book now.
See her most recent paper Eligibility for antiamyloid treatment zurl.co/KqOak
See her most recent paper Eligibility for antiamyloid treatment zurl.co/KqOak
Vascular Neurology Considerations for Antiamyloid Immunotherapy: Science Advisory from American Heart Association. Affirmed by AAN.
❌Anticoagulants: exclude from immunotherapy
❌Thrombolytics: avoid until date demonstrating safety are available
Link: www.ahajournals.org/doi/epdf/10....
❌Anticoagulants: exclude from immunotherapy
❌Thrombolytics: avoid until date demonstrating safety are available
Link: www.ahajournals.org/doi/epdf/10....
December 11, 2024 at 11:41 PM
Vascular Neurology Considerations for Antiamyloid Immunotherapy: Science Advisory from American Heart Association. Affirmed by AAN.
❌Anticoagulants: exclude from immunotherapy
❌Thrombolytics: avoid until date demonstrating safety are available
Link: www.ahajournals.org/doi/epdf/10....
❌Anticoagulants: exclude from immunotherapy
❌Thrombolytics: avoid until date demonstrating safety are available
Link: www.ahajournals.org/doi/epdf/10....